PROEHL GERALD T - 21 Jan 2025 Form 4 Insider Report for Dermata Therapeutics, Inc. (DRMA)

Role
President, CEO and Chairman, Director, 10%+ Owner
Signature
/s/ Gerald T. Proehl
Issuer symbol
DRMA
Transactions as of
21 Jan 2025
Net transactions value
$0
Form type
4
Filing time
23 Jan 2025, 17:02:08 UTC
Previous filing
14 Jan 2025
Next filing
03 Jul 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DRMA Common Stock Award +787,402 +6504% 799,508 21 Jan 2025 By Proehl Investment Ventures LLC F1, F2, F4
holding DRMA Common Stock 247 21 Jan 2025 Direct
holding DRMA Common Stock 74 21 Jan 2025 By Allison Taylor Proehl 2020 Irrevocable Trust F4
holding DRMA Common Stock 37 21 Jan 2025 By Meghan Proehl Wilder 2020 Irrevocable Trust F4
holding DRMA Common Stock 149 21 Jan 2025 By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020 F4
holding DRMA Common Stock 595 21 Jan 2025 By Proehl Family Trust F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DRMA Warrant (Right to Buy) Award +787,402 787,402 21 Jan 2025 Common Stock 787,402 $1.27 By Proehl Investment Ventures LLC F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of Common Stock and accompanying Warrant were purchased by the Reporting Person from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
F2 The purchase price per share of Common Stock and accompanying Warrant was $1.27.
F3 The Warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the warrants. The Warrant will expire five years from the effective date of stockholder approval. The Warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise, subject to certain exceptions.
F4 Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.